{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:52:54Z","timestamp":1792417974099,"version":"4.4.0"},"reference-count":12,"publisher":"The Endocrine Society","issue":"1","funder":[{"name":"Division of Intramural Research NICHD"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Multiple endocrine neoplasia type 2B (MEN2B) is characterized by early-onset medullary thyroid cancer in virtually all cases and a 50% lifetime risk of pheochromocytoma (PHEO) development. The literature on PHEO in patients with MEN2B is limited with most data being reported from adult studies that primarily address MEN2A.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of the current study is to describe PHEO development in a cohort of pediatric patients with MEN2B.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective chart review of patients with MEN2B evaluated at the National Institutes of Health in the period between July 2007 and February 2018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 38 patients were identified (21 males and 17 females). Mean age at MEN2B diagnosis was 10.6 \u00b1 3.9 years. Eight patients (21%) developed PHEO in the course of follow-up to date, all of whom were sporadic cases with the classic M918T RET mutation. PHEO was diagnosed based on biochemical and\/or imaging screening studies in five patients, whereas three patients presented with symptoms of excess catecholamines. PHEO was diagnosed at a mean age 15.2 \u00b1 4.6 (range, 10 to 25) years and 4.0 \u00b1 3.3 years after MEN2B diagnosis. Only one patient was diagnosed with PHEO as the initial manifestation of MEN2B after she presented with hypertension and secondary amenorrhea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Undiagnosed PHEO can be associated with substantial morbidity. Current American Thyroid Association guidelines recommend PHEO screening starting at age 11 for the high-\/highest risk group. The youngest patient diagnosed with PHEO in our cohort was an asymptomatic 10-year-old, suggesting that PHEO development may begin before the screening-recommended age of 11, though remains clinically undetectable and thus the current screening guidelines seem appropriate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-00705","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T18:36:12Z","timestamp":1533234972000},"page":"7-12","source":"Crossref","is-referenced-by-count":18,"title":["Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B"],"prefix":"10.1210","volume":"104","author":[{"given":"Angeliki","family":"Makri","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivandana","family":"Akshintala","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"},{"name":"Division of Pediatric Hematology\/Oncology, School of Medicine, New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Derse-Anthony","sequence":"additional","affiliation":[{"name":"Clinical Research Directorate\/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Widemann","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A","family":"Stratakis","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glod","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Lodish","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"4","key":"2020071622215579200_B1","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.91.4.1579","article-title":"Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6461","key":"2020071622215579200_B2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"issue":"2","key":"2020071622215579200_B3","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/ERC-17-0209","article-title":"A comprehensive review on MEN2B","volume":"25","author":"Castinetti","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2020071622215579200_B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2020071622215579200_B5","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1210\/jcem.82.11.4508","article-title":"Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation","volume":"82","author":"Gimm","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071622215579200_B6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182a6f43a","article-title":"Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective","volume":"259","author":"Brauckhoff","year":"2014","journal-title":"Ann Surg"},{"issue":"6","key":"2020071622215579200_B7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"11","key":"2020071622215579200_B8","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071622215579200_B9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/eje.0.1440037","article-title":"Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study","volume":"144","author":"Nguyen","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2020071622215579200_B10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jso.23378","article-title":"Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening","volume":"108","author":"Rowland","year":"2013","journal-title":"J Surg Oncol"},{"issue":"16","key":"2020071622215579200_B11","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/jnci\/djg024","article-title":"Pheochromocytoma: the expanding genetic differential diagnosis","volume":"95","author":"Bryant","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2020071622215579200_B12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.surg.2008.08.028","article-title":"Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis","volume":"144","author":"Brauckhoff","year":"2008","journal-title":"Surgery"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/1\/7\/26620446\/jc.2018-00705.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/1\/7\/26620446\/jc.2018-00705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:40:41Z","timestamp":1594982441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/1\/7\/5063485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-00705","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,8,2]]}}}